Tropisetron Capsules Suppliers & Bulk Manufacturers
Available Forms: Capsules
Available Strengths: 5 mg
Reference Brands: Navoban(EU & Asia)
Category:
Antiemetic
Tropisetron is a 5-HT3 receptor antagonist that blocks serotonin in the gastrointestinal tract and brain, preventing nausea and vomiting. It effectively reduces chemo- and post-operative nausea, improves patient comfort, supports treatment adherence, and enhances quality of life during cancer therapy or surgery.
Tropisetron Capsules is available in Capsules
and strengths such as 5 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Tropisetron Capsules is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Tropisetron Capsules can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Tropisetron tablets, marketed as Navoban in the EU and available as generic formulations, are approved in the US by the FDA and in the EU via EMA for preventing nausea and vomiting induced by chemotherapy and surgery. Approval requires a detailed dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. The FDA reviews comprehensive clinical trial and quality information for timely approval, while the EMA ensures regional safety and manufacturing compliance. For guidance on dossier preparation, regulatory pathways, and market access, visit PharmaTradz. Proper regional adherence supports swift approval, safe use, and global availability, aiding effective management of chemotherapy-induced nausea worldwide.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing